Efficacy of miltefosine therapy against subcutaneous experimental pythiosis in rabbits

J Mycol Med. 2020 Apr;30(1):100919. doi: 10.1016/j.mycmed.2019.100919. Epub 2019 Dec 16.

Abstract

We evaluated the in vitro activity of miltefosine against 29 Pythium spp. and the in vivo therapeutic response of 2mg/kg/day of miltefosine given orally to rabbit with pythiosis induced experimentally. The MICs (in μg/mL) of miltefosine was medium-dependent and ranged from 0.5 to 2 and 32-64 on RPMI 1640 and Mueller Hinton broth, respectively. The treatment with miltefosine demonstrated significantly lower subcutaneous lesion areas compared to the control group but was not sufficient for the complete remission of the lesions. This study indicates that miltefosine has limited efficacy against pythiosis and furthers in vitro and in vivo studies are necessary to determine the possible potential of this drug in the treatment of pythiosis.

Keywords: Oomycete; Pythium insidiosum; Treatment.

MeSH terms

  • Animals
  • Antifungal Agents / therapeutic use*
  • Dermatomycoses / drug therapy*
  • Dermatomycoses / microbiology
  • Dermatomycoses / pathology
  • Disease Models, Animal
  • Disease Progression
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Microbial Sensitivity Tests
  • Phosphorylcholine / analogs & derivatives*
  • Phosphorylcholine / therapeutic use
  • Pythiosis / drug therapy*
  • Pythiosis / microbiology
  • Pythiosis / pathology
  • Pythium / isolation & purification
  • Pythium / pathogenicity
  • Rabbits
  • Subcutaneous Tissue / microbiology
  • Treatment Outcome

Substances

  • Antifungal Agents
  • Phosphorylcholine
  • miltefosine